Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
E. Heo (Seoul, Republic of Korea), M. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), H. Chung (Seoul, Republic of Korea). Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance.. 2854

Member's Comments

No comment yet.

Related content which might interest you: Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009 SiRNA mediated growth factor receptors inhibition in A549 cell model of lung cancer gene therapy: insulin-like growth factor-I receptor (IGF-R1) blockade produces changes that potentially induce anti-tumor immunity Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Protease activated receptor-1 (PAR-1) stimulation leads to αvβ6 integrin mediated TGFβ activation via rho kinase Source: Eur Respir J 2005; 26: Suppl. 49, 238s Year: 2005 Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Inhibition of VEGF blocks TGF-β1 production through a PI3K/Akt signalling pathway Source: Eur Respir J 2008; 31: 523-531 Year: 2008 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 G-protein mediated EGFR transactivation induces mucin production Source: Annual Congress 2003 - Cellular and molecular mechanisms in epithelium injury and repair Year: 2003 Understanding the mechanisms of TKIs: the cycle of inhibition and resistance Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 Glucocorticoids promote TGF-β signalling in lung fibroblasts by upregulating ligand and receptor expression, and uncoupling negative-feedback inhibition Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012